ociation of the Variants CASP 8 D 302 H and CASP 10 0 I with Breast and Ovarian Cancer Risk in B & P A 1 and BRCA 2 Mutation Carriers

oph Engel, Beatrix Versmold, Barbara Wappenschmidt, Jacques Simard, Douglas F. Easton, Susan Peock, ret Cook, Clare Oliver, Debra Frost, Rebecca Mayes, D. Gareth Evans, Rosalind Eeles, Joan Paterson, Brewer ; for the Epidemiological Study of Familial Breast Cancer (EMBRACE), Lesley McGuffog, is C. Antoniou, Dominique Stoppa-Lyonnet, Olga M. Sinilnikova, Laure Barjhoux, Marc Frenay, Michel, Dominique Leroux, Helene Dreyfus, Christine Toulas, Laurence Gladieff, Nancy Uhrhammer, Jean Bignon, Alfons Meindl, Norbert Arnold, Raymonda Varon-Mateeva, Dieter Niederacher, e Preisler-Adams, Karin Kast, Helmut Deissler, Christian Sutter, Dorothea Gadzicki, ia Chenevix-Trench, Amanda B. Spurdle, Xiaoqing Chen, Jonathan Beesley; for the Kathleen gham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Håkan Olsson, istoffersson, Hans Ehrencrona, Annelie Liljegren; for the Swedish Breast Cancer Study, Sweden (SWE-BRCA), . van der Luijt, Theo A. van Os, Flora E. van Leeuwen; for the Hereditary Breast and Ovarian cancer Netherlands (HEBON), Susan M. Domchek, Timothy R. Rebbeck, Katherine L. Nathanson, Ana Osorio, a Ramón y Cajal, Irene Konstantopoulou, Javier Benítez, Eitan Friedman, Bella Kaufman, Yael Laitman, g L. Mai, Mark H. Greene, Heli Nevanlinna, Kristiina Aittomäki, Csilla I. Szabo, Trinidad Caldes, s J. Couch, Irene L. Andrulis, Andrew K. Godwin, Ute Hamann, and Rita K. Schmutzler; half of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)